STOCK TITAN
  1. Home
  2. News
  3. DBVT

DBV Technologies - DBVT STOCK NEWS

Welcome to our dedicated news page for DBV Technologies (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on DBV Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DBV Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DBV Technologies's position in the market.

News
Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024
Rhea-AI Summary
DBV Technologies (DBVT) reports a total of 96,434,369 shares and 96,171,725 voting rights as of March 31, 2024, on the NYSE Euronext Paris.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
none
-
News
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
Rhea-AI Summary
DBV Technologies files its 2023 Annual Report on Form 10-K and Universal Registration Document, showcasing its commitment to transparency and regulatory compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
none
-
News
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
Rhea-AI Summary
DBV Technologies reported its full-year 2023 financial results, highlighting progress in Viaskin Peanut clinical development programs for peanut-allergic toddlers and children. The company strengthened its executive team for BLA submission and reported cash and cash equivalents of $141 million. Despite delays due to new regulations, enrollment in the VITESSE trial is ongoing, with good momentum expected. Operational highlights include positive results from EPITOPE and initiation of safety trials. Financially, DBV saw a net decrease in cash and cash equivalents, used $79.6 million in operations primarily in R&D, and recorded a net loss of $72.7 million. The company plans to seek additional capital as it continues R&D efforts and prepares for the launch of Viaskin Peanut.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
earnings
News
DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
Rhea-AI Summary
DBV Technologies will report full year 2023 financial results and provide a business update on March 7, 2024. The conference call and webcast will be held at 5:00 p.m. ET. Interested participants can access the call via teleconferencing numbers or the live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
conferences earnings
-
News
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
Rhea-AI Summary
DBV Technologies to present at AAAAI 2024 Congress on peanut allergy treatments. Two presentations on Viaskin Peanut safety and immune effects in children. Sponsorship of Product Theater and FIT Program reception.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
conferences
-
News
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Rhea-AI Summary
DBV Technologies issued a Half-Year report on its liquidity contract with NATIXIS ODDO BHF, revealing an increase in the number of shares and a decrease in the liquidity account balance. The report also detailed the executed transactions and the volumes traded during the period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
none
News
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023  
Rhea-AI Summary
Company XYZ (Ticker: XYZ) Reports Total Number of Voting Rights and Shares as of November 30, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.29%
Tags
none
-
News
DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers
Rhea-AI Summary
DBV Technologies (DBVT) Announces Positive 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers. The results showed significant improvement in efficacy parameters, with 81.3% of subjects reaching an eliciting dose of ≥1,000 mg after 24 months of treatment. DBV will highlight these results at the ACAAI annual meeting and host an investor conference call to discuss the findings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
clinical trial
-
News
Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023
Rhea-AI Summary
The Company has reported the total number of shares and voting rights as of October 31, 2023. The total number of shares is 96,288,553. The total gross of voting rights is 96,288,553, and the total net of voting rights is 96,084,083.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
none
News
DBV Technologies to Present New Data at ACAAI 2023
Rhea-AI Summary
DBV Technologies will present new data on the use of Viaskin Peanut in peanut-allergic toddlers at the ACAAI 2023 Annual Scientific Meeting. The data will include interim 12-month results from the ongoing Phase 3 open-label extension to the EPITOPE trial. Viaskin Peanut is the Company's lead product candidate designed to reduce the risk of allergic reactions to peanuts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
conferences
Stock DBVT logo
DBV Technologies

Nasdaq:DBVT

DBVT Rankings

#4063 Ranked by Market Cap
#3835 Ranked by Stock Gains
N/A Ranked by Dividends

DBVT Stock Data

133.56M
43.83M
19.64%
0.29%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
France
Montrouge

About DBVT

dbv technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. dbv technologies (incorporated in 2002) has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. the viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. the product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. dbv technologies is focusing on food allergies (milk and